Business and Finance

Sector is anticipated to grow at a CAGR of 9.3%.

The Vicenza site will run about 54,000 square feet in size.

Value is attributed to the rise in counterfeit cases and ongoing regulations surrounding anti-counterfeit packaging.

CDMO’s goal is to increase building’s aseptic manufacturing capacity.

Acquisition helps expand pharma marketing reach and opens door for growth opportunities.

The conference will focus on the full breadth of commercialization strategies and operations.

Acquisition includes company’s inflammatory disease medicines.

Purchase allows company to provide a fully integrated small-to-medium scale sterile injectable service offering for the biopharma industry.

The newly established business under Advent International and Warburg Pincus will be named Simtra BioPharma Solutions.

Deal—expected to be finalized by the end of the year—grows the logistics provider’s healthcare capabilities.

Manufacturing capacity of company’s High Point facility now doubles as a result.

The latest people news happenings over the past month.

The trend is continuing for brands and even for some specialty products.

Shares expected to be offered on Six Swiss Exchange.

This would signify an 8.3% CAGR over the next five years.

Max Sauberschwarz will become the Group's newest EVP this October.

Strategy includes a layoff of nearly 400 employees.

Karin Van Den Brekel, Niall Walsh hired to manage EMEA and Ireland respectively.

Stephanie Smith Cooney joins PBM business to further develop partnerships, especially with independent pharmacists in local communities.

Companies' emphasis on delivering pharmaceuticals is evolving into a collaboration focused on healthcare outcomes.

Executive joins PTC with finance strategy experience, particularly as it pertains to biopharma.

Agency claims union would threaten a monopoly on programmatic advertising space.

Executive succeeds Ken Paulus as head of the PBM.

Crain’s Chicago Business distinction—based on revenue performance—is the second honor in just as many years for the transportation 3PL.

In this latest Harvard Business School Healthcare Alumni Association Q&A, Ayelet Israeli, PhD, explains the potential—as well as limitations—of these offerings and pragmatic guardrails for deployment in organizations.